MediLink Therapeutics (Suzhou) Co Ltd, a China-based clinical-stage biotech company, announced on Monday that it has entered into a global clinical trial collaboration and supply agreement with US biopharmaceutical company Amgen Inc (NASDAQ:AMGN).
Under the agreement, Amgen will lead a global clinical study to assess the therapeutic potential of the combination of MediLink's B7-H3-targeting antibody-drug conjugate (ADC) YL201 and Amgen's DLL3- and CD3-targeting bispecific T-cell engager (BiTE) IMDELLTRA in extensive-stage small cell lung cancer (ES-SCLC). MediLink will provide the investigational drug YL201 for the combination study.
The open-label, multi-centre Phase Ib trial is aimed at assessing the safety, tolerability, pharmacokinetics and efficacy of this combination regimen in ES-SCLC patients.
Both YL201 and IMDELLTRA have shown potential in ES-SCLC.
Galmed reveals novel pharmacodynamic blood markers for Aramchol SCD1 inhibitor
Evommune initiates EVO756 Phase 2b trial in adults with chronic spontaneous urticaria
Telix Pharmaceuticals' TLX101 glioma therapy candidate shows promising efficacy
FluoGuide begins phase II trial of FG001 for head and neck cancer
Sanofi advances respiratory pipeline with positive amlitelimab data and expanded clinical programmes
PRISM BioLab agrees drug discovery collaboration with Elix
Sumitomo Pharma America signs research and development agreement with NCI
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Genflow Biosciences enters into AI-driven research agreement with Heureka Labs
Sichuan Kelun-Biotech reveals sacituzumab tirumotecan (sac-TMT) clinical studies results
Kyowa Kirin completes construction of new Drug Substance manufacturing facility
Amgen's IMDELLTRA shows superior overall survival in small cell lung cancer trial
OncoZenge AB signs licensing deal with Avernus Pharma for BupiZenge in GCC region